Hi Elysian I was thinking that the next report would disappoint the market because of this last report, But you seem to think otherwise is that correct.
11 June 2004 SciGen Limited SciGen to Manufacture Hep B Vaccine and Increase Market Coverage Asia-Pacific rights for SciGen to develop and market a therapeutic Vaccine developed from Sci-B-Vac for the treatment of hepatitis. SciGen intends to initiate manufacturing in India with its local partner, Shreya Biotech, and will consider another Asian manufacturing site at a later stage. SciGen has secured the assistance of an expert technical team, formerly of Savient, to supervise the process of technology transfer which will take approximately six months. This will result in a temporary interruption to supply of the vaccine and a consequent effect on SciGen�fs revenue which SciGen expects to be offset by other benefits from the new license agreement.
SIE Price at posting:
0.0¢ Sentiment: None Disclosure: Not Held